Arab Journal of Gastroenterology
Volume 11, Issue 1 , Pages 24-29 , March 2010

Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis

  • Ehab E. Abdel-Khalek

      Affiliations

    • Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
    • Corresponding Author InformationCorresponding author. Tel.: +20 50 22 22 966.
    • ,
  • Salah E. Arif

      Affiliations

    • Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Received 11 December 2009 ,Accepted 11 January 2010.

References 

  1. Choudhury J, Sanya AJ. Treatment of ascites. Curr Treat Options Gastroenterol. 2003;6(6):481–491
  2. Saadeh S, Davis GL. Management of ascites in patients with end-stage liver disease. Rev Gastroenterol Disord. 2004;4(4):175–185
  3. Kuiper JJ, van Buuren HR, de Man RA. Ascites in cirrhosis: a review of management and complications. Neth J Med. 2007;65(8):283–288
  4. Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009;15(1):67–80
  5. Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am. 2009;93(4):801–817
  6. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94(6):1493–1502
  7. McGibbon A, Chen GI, Peltekian KM, et al. An evidence-based manual for abdominal paracentesis. Digest Dis Sci. 2007;52(12):3307–3315
  8. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37(5):1147–1153
  9. Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology. 2009;50(2):555–564
  10. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull. 2002;25(6):695–704
  11. Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem. 2002;9(15):1463–1481
  12. Roche M, Rondeau P, Singh NR, et al. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783–1787
  13. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111(4):1002–1010
  14. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. New Engl J Med. 1999;341(6):403–409
  15. Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. results of a randomized study. Gastroenterology. 1990;99(6):1736–1744
  16. Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology. 1991;13(4):707–713
  17. Fassio E, Terg R, Landeira G, et al. Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol. 1992;14(2–3):310–316
  18. Altman C, Bernard B, Roulot D, et al. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol. 1998;10(1):5–10
  19. Garcia-Compean D, Blanc P, Larrey D, et al. Treatment of cirrhotic tense ascites with dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol. 2002;1(1):29–35
  20. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology. 1990;98(1):146–151
  21. El Garem N, Fathi A, El Amir M, et al. Effects of large volume abdominal paracentesis combined with plasma volume expansion on portal venous dynamics. New Egypt J Med. 1997;16(3):281–285
  22. Munro BH. Statistical methods for health care research. 4th ed.. Anonymous Lippincott Williams & Wilkins; 2002;
  23. Hussain S, Hawass ND, Zaidi AJ. Ultrasonographic diagnosis of schistosomal periportal fibrosis. J Ultrasound Med. 1984;3(10):449–452
  24. Arroyo V, Gines A, Salo J. A European survey on the treatment of ascites in cirrhosis. J Hepatol. 1994;21(4):667–672
  25. Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994;106(3):709–719
  26. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology. 1995;22(3):753–758
  27. Cabrera J, Inglada L, Quintero E, et al. Large-volume paracentesis and intravenous saline: Effects on the renin–angiotensin system. Hepatology. 1991;14(6):1025–1028
  28. Boyer JL, Maddrey WC, Basu AK, et al. The source of albumin in the thoracic duct lymph in patients with portal hypertension and ascites. Am J Med Sci. 1969;257(1):32–43
  29. Vogt H, Reinetlt H. Oncotic function of plasma in high dose colloid infusion: long term comparison between HES200/0.5 6% and human albumin (HA) 5%. Anaesthesia. 1991;40(Suppl. 1):

PII: S1687-1979(10)00007-9

doi: 10.1016/j.ajg.2010.01.006

Arab Journal of Gastroenterology
Volume 11, Issue 1 , Pages 24-29 , March 2010

Article Tools